Premium
Thinking About Broadly Cross‐Reactive Vaccines
Author(s) -
Doherty PC,
Turner SJ
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.52
Subject(s) - ctl* , cytotoxic t cell , glycoprotein , virology , antibody , biology , secretion , cd8 , immunology , neutralization , virus , human immunodeficiency virus (hiv) , immune system , genetics , in vitro , biochemistry
Successful vaccines function almost exclusively by establishing long‐lived plasma cells that secrete antibody into the blood and at mucosal sites. Some pathogens, such as HIV and the influenza A viruses, use a mutational strategy to escape neutralization by antibodies specific for surface glycoproteins. The CD8 + cytotoxic T–lymphocyte (CTL) response is, on the other hand, directed mostly at peptides derived from conserved, internal virus proteins. Can CTL memory be manipulated to provide cross‐reactive protection?